Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Closes Offering of 8,050,000 Shares

WILMINGTON, Mass.--(BW HealthWire)--March 21, 2001--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it closed its public offering of 8,050,000 shares of common stock (which included the underwriters' over-allotment option to purchase an additional 1,050,000 shares) at $19 per share. Of the 8,050,000 shares, 3,500,000 were sold by the Company and 4,550,000 were sold by selling stockholders. The joint lead managers for the offering were Credit Suisse First Boston and Lehman Brothers.

--30--jr/bos*

CONTACT: Dennis R. Shaughnessy
Marcia Gookin
978-658-6000 ext. 1329
ir@criver.com


Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)